S
Scot Richard Mente
Researcher at Pfizer
Publications - 42
Citations - 1087
Scot Richard Mente is an academic researcher from Pfizer. The author has contributed to research in topics: Casein kinase 1 & Schizophrenia. The author has an hindex of 17, co-authored 41 publications receiving 949 citations. Previous affiliations of Scot Richard Mente include Pennsylvania State University.
Papers
More filters
Journal ArticleDOI
Solvation and the Excited-State Tautomerization of 7-Azaindole and 1-Azacarbazole: Computer Simulations in Water and Alcohol Solvents
TL;DR: In this paper, computer simulations are performed in order to investigate the role of hydroxylic solvents in catalyzing the excited-state tautomerization of 7-azaindole (7-AI) and 1-azacarbazole (1-AC).
Journal ArticleDOI
Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.
Allen J. Duplantier,Stacey L. Becker,Michael John Bohanon,Kris A. Borzilleri,Boris A. Chrunyk,James T. Downs,Lain-Yen Hu,Ayman El-Kattan,Larry C. James,Shenping Liu,Jiemin Lu,Noha Maklad,Mahmoud N. Mansour,Scot Richard Mente,Mary Piotrowski,Subas M. Sakya,Sheehan Susan M,Stefanus J. Steyn,Christine A. Strick,Victoria A. Williams,Lei Zhang +20 more
TL;DR: Subsequent evaluation against the rat DAAO enzyme revealed a divergent SAR versus the human enzyme and may explain the high exposures of drug necessary to achieve significant changes in rat or mouse cerebellum D-serine.
Journal ArticleDOI
Computer simulations of the solvatochromism of betaine-30
TL;DR: In this paper, Monte Carlo simulations of the pyridinium N-phenolate dye "Betaine-30" in 12 solvents (20 solvent representations) were performed in order to explore the molecular basis of the ET(30) scale of solvent polarity.
Journal ArticleDOI
Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764).
Travis T. Wager,Betty Pettersen,Anne W. Schmidt,Douglas K. Spracklin,Scot Richard Mente,Butler Todd W,Howard Harry R,Daniel J. Lettiere,David M. Rubitski,Diane F. Wong,Frank M. Nedza,Frederick R. Nelson,Hans Rollema,Raggon Jeffrey W,Jiri Aubrecht,Jody Freeman,John M. Marcek,Julie Cianfrogna,Karen W. Cook,Larry C. James,Linda A. Chatman,Philip A. Iredale,Michael J. Banker,Michael Homiski,Jennifer B. Munzner,Rama Y. Chandrasekaran +25 more
TL;DR: Overall, clinical compounds 6 and 7 exceeded conservative safety margins and possessed optimal pharmacological and pharmacokinetic profiles, thus achieving the initial goal of identifying compounds with fully aligned oral drug attributes, "best-in-class" molecules.
Journal ArticleDOI
Potent α-Synuclein Aggregation Inhibitors, Identified by High-Throughput Screening, Mainly Target the Monomeric State.
Martin Kurnik,Cagla Sahin,Camilla Bertel Andersen,Nikolai Lorenzen,Lise Giehm,Hossein Mohammad-Beigi,Hossein Mohammad-Beigi,Christian Moestrup Jessen,Jan Skov Pedersen,Gunna Christiansen,Steen V. Petersen,Roland G.W. Staal,Girija Krishnamurthy,Keith Pitts,Peter H. Reinhart,Frans A. A. Mulder,Scot Richard Mente,Warren D. Hirst,Daniel E. Otzen +18 more
TL;DR: A high-throughput screening assay combining SDS-stimulated αSN aggregation with FRET to reproducibly detect initial stages inαSN aggregation is developed and several phenyl-benzoxazol compounds that promoted α SN aggregation (proaggregators) are identified, which may be useful tools to modulate β-Synuclein aggregation in cellula.